Page 47 - 《中国药房》2024年8期
P. 47

[ 5 ]  李尚颖,岳青阳,张耀文,等 . GC-MS/MS 法同时测定氯             [12]  ICH. Assessment and control of DNA reactive(mutagenic)
              沙坦钾原料药及其制剂中 6 种 N-亚硝胺类基因毒性杂                         impurities  in  pharmaceuticals  to  limit  potential  carcino‐
              质[J]. 中国药房,2023,34(15):1830-1834.                   genicrisk[EB/OL]. [2023-08-10]. https://database. ich. org/
              LI S Y,YUE Q Y,ZHANG Y W,et al. Simultaneous de‐    sites/default/files/ICH_M7%28R2%29_Guideline_Step4_
              termination of 6 kinds of N-nitrosamines genotoxic impu‐  2023_0216_0.pdf.
              rities in losartan potassium raw material and its formula‐  [13]  贺美莲,郭常川,石峰,等. Orbitrap高分辨质谱技术在药
              tions  by  GC-MS/MS[J].  China  Pharm,2023,34(15):  物分析领域中的应用进展[J]. 药物分析杂志,2019,39
              1830-1834.                                         (1):105-110.
          [ 6 ]  黄海伟,袁松,张龙浩,等. 超高效液相色谱-串联质谱法                      HE M L,GUO C C,SHI F,et al. Application progress of
              测定厄贝沙坦和氯沙坦钾原料药中 3 种叠氮类基因毒                           Orbitrap high-resolution mass spectrometry in the field of
              性杂质[J]. 中国新药杂志,2023,32(7):742-746.                  pharmaceutical analysis[J]. Chin J Pharm Anal,2019,39
              HUANG H W,YUAN S,ZHANG L H,et al. Determina‐       (1):105-110.
              tion of three azides genotoxic impurities in irbesartan and   [14]  ZHANG S,POWELL M L,NELSON W L,et al. Deriva‐
              losartan  potassium  active  pharmaceutical  ingredients  by   tives of beta-adrenergic antagonists: N-nitrosopropranolol
              UPLC-MS/MS[J]. Chin J N Drugs,2023,32(7):742-746.   and  N-hydroxypropranolol  and  its  aldonitrone[J].  J  Med
          [ 7 ]  ALIZADEH  T,ALLAHYARI  L.  Highly-selective  deter‐  Chem,1983,26(3):455-458.
              mination  of  carcinogenic  derivative  of  propranolol  by      [15]  SOTTOFATTORI E,MARTELLI A,BRAMBILLA G. Ef‐
              using  a  carbon  paste  electrode  incorporated  with  nano-  fects of mono-,di- and tri-hydroxybenzoic acids on the ni‐
              sized  propranolol-imprinted  polymer[J].  Electrochim   trosation of propranolol:structure-activity relationship[J].
              Acta,2013,111:663-673.                              Mutat Res,2001,490(1):81-88.
          [ 8 ]  韩 中 惠 ,王 晓 敏 ,张 燕 ,等 .  应 用 Discovery  Studio  [16]  田珩,吴纯敏,贝琦华. 离子色谱法测定雷尼替丁原料药
              (TOPKAT)软件预测糖抑制 PhIP 过程中新产物的毒理                      及制剂中亚硝酸根含量[J]. 中国药业,2021,30(15):
              学性质[J]. 中国食品学报,2020,20(10):247-253.                 74-77.
              HAN Z H,WANG X M,ZHANG Y,et al. Prediction of       TIAN H,WU C M,BEI Q H. Content determination of ni‐
              toxicological  properties  of  new  products  in  sugar  inhibi‐  trite  ion  in  ranitidine  raw  materials  and  preparations  by
              tion  of  PhIP  by  Discovery  Studio(TOPKAT)[J].  J  Chin   ion  chromatography[J].  China  Pharm,2021,30(15):
              Inst Food Sci Technol,2020,20(10):247-253.          74-77.
          [ 9 ]  HAN Y,ZHANG J P,HU C Q,et al. In silico ADME and   [17]  叶晓霞,葛雨琦,乐健,等. 缓释制剂辅料导致盐酸二甲
              toxicity  prediction  of  ceftazidime  and  its  impurities[J].   双胍降解产生 N-亚硝基二甲胺的影响因素研究[J]. 药
              Front Pharmacol,2019,10:434.                        物分析杂志,2021,41(2):293-299.
          [10]  WU B,ZHANG Z Y,DOU G J,et al. Novel natural in‐   YE X X,GE Y Q,LE J,et al. Study on influencing factors
              hibitors targeting B-RAF(V600E)by computational study  of  metformin  hydrochloride’s  degradation  to  N-nitro-
              [J]. Bioengineered,2021,12(1):2970-2983.            sodimethylamine  induced  by  sustained-release  excipients
          [11]  ZHONG S,ZHANG Z Y,GUO Z,et al. Identification of   [J]. Chin J Pharm Anal,2021,41(2):293-299.
              novel  natural  inhibitors  targeting  AKT  serine/threonine     (收稿日期:2023-09-28  修回日期:2024-02-01)
              kinase  1(AKT1)by  computational  study[J].  Bioengi‐                               (编辑:张元媛)
              neered,2022,13(5):12003-12020.




















          中国药房  2024年第35卷第8期                                                 China Pharmacy  2024 Vol. 35  No. 8    · 941 ·
   42   43   44   45   46   47   48   49   50   51   52